Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Invitrogen

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 14 November 1969:
Vol. 166. no. 3907, pp. 899 - 901
DOI: 10.1126/science.166.3907.899
Prev | Table of Contents | Next

Articles

Antiparkinsonian Drugs: Inhibition of Dopamine Uptake in the Corpus Striatum as a Possible Mechanism of Action

Joseph T. Coyle 1 and Solomon H. Snyder 1

1 Departments of Pharmacology and Experimental Therapeutics and Psychiatry and the Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

A variety of antiparkinsonian drugs are potent, noncompetitive inhibitors of dopamine uptake into synaptosomes in homogenates of rat corpus striatum. Inhibition of dopamine uptake may potentiate the synaptic actions of dopamine in the striatum and could explain the antiparkinsonian effects of these drugs. This hypothesis accounts for several clinical features of Parkinson's disease and predicts compounds which may be new therapeutic agents.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Dopamine Transporter (DAT) Inhibitors Alleviate Specific Parkinsonian Deficits in Monkeys: Association with DAT Occupancy in Vivo.
B. K. Madras, M. A. Fahey, M. Goulet, Z. Lin, J. Bendor, C. Goodrich, P. C. Meltzer, D. R. Elmaleh, E. Livni, A. A. Bonab, et al. (2006)
J. Pharmacol. Exp. Ther. 319, 570-585
   Abstract »    Full Text »    PDF »
Variable Effects of Previously Untested Muscarinic Receptor Antagonists on Experimental Myopia.
W. A. Luft, Y. Ming, and W. K. Stell (2003)
Invest. Ophthalmol. Vis. Sci. 44, 1330-1338
   Abstract »    Full Text »    PDF »
Forty Years of Neurotransmitters: A Personal Account.
S. H. Snyder (2002)
Arch Gen Psychiatry 59, 983-994
   Abstract »    Full Text »    PDF »
Anticholinergic drugs: response of parkinsonism not responsive to levodopa.
H Yamada, T Momose, M Okada, and Y Kuroiwa (2002)
J. Neurol. Neurosurg. Psychiatry 72, 111-113
   Abstract »    Full Text »    PDF »
Cholinergic Neuronal Modulation Alters Dopamine D2 Receptor Availability In Vivo by Regulating Receptor Affinity Induced by Facilitated Synaptic Dopamine Turnover: Positron Emission Tomography Studies with Microdialysis in the Conscious Monkey Brain.
H. Tsukada, N. Harada, S. Nishiyama, H. Ohba, and T. Kakiuchi (2000)
J. Neurosci. 20, 7067-7073
   Abstract »    Full Text »    PDF »
Novel 3alpha -Diphenylmethoxytropane Analogs: Selective Dopamine Uptake Inhibitors with Behavioral Effects Distinct from Those of Cocaine.
J. L. Katz, S. Izenwasser, R. H. Kline, A. C. Allen, and A. H. Newman (1999)
J. Pharmacol. Exp. Ther. 288, 302-315
   Abstract »    Full Text »
Direct in vivo monitoring of dopamine released from two striatal compartments in the rat.
A. Ewing, J. Bigelow, and R. Wightman (1983)
Science 221, 169-171
   Abstract »    PDF »
Adenosine 3',5'-Monophosphate Content in Rat Caudate Nucleus: Demonstration of Dopaminergic and Adrenergic and Receptors.
J. Forn, B. K. Krueger, and P. Greengard (1974)
Science 186, 1118-1120
   Abstract »    PDF »
Overeating and Obesity from Damage to a Noradrenergic System in the Brain.
J. E. Ahlskog and B. G. Hoebel (1973)
Science 182, 166-169
   Abstract »    PDF »
Amphetamine: Differentiation by d and I Isomers of Behavior Involving Brain Norepinephrine or Dopamine.
K. M. Taylor and S. H. Snyder (1970)
Science 168, 1487-1489
   Abstract »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)